# ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
Canonical URL: https://biopharmsignal.com/news/PMN/promis-neurosciences-to-participate-in-upcoming-conferences-and-events-in-septem-72fbc0d5
Ticker: PMN
Company: ProMIS Neurosciences
Source: ProMIS Neurosciences
Published: 2026-09-01 12:00 EST
## Summary

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody...

## Article Body
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.

Conference details below:

September 9-11: Cantor Global Healthcare Conference Location: New York, NY Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief Executive Officer Webcast link: Click Here

September 9-10: Moody Capital Disruptive Growth & Life Sciences Conference Location: New York, NY Presentation: Thursday, September 10, 1:45-2:05 p.m. ET, Room 1 Webcast link: Click Here

September 14-16: H.C. Wainwright 28 th Annual Global Investment Conference Location: New York, NY Presentation: Tuesday, September 15, 10:30-11:00 a.m. ET, Louis Room (4 th floor) Webcast link: Click Here

September 21 (World Alzheimer’s Day): ProMIS Neurosciences and Nasdaq mark World Alzheimer’s Day at the Nasdaq Tower Location: Nasdaq Tower, New York, NY

September 29: Roth Healthcare Opportunities Conference Location: New York, NY

During these conferences, Neil Warma, President & Chief Executive Officer of ProMIS Neurosciences, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations & External Affairs, will discuss the Company’s EpiSelect™ platform, its differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, and PMN310, the Company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease.

ProMIS reported blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in July 2026, with 12-month topline data anticipated in early 2027.

Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available in the Investors section of the website.

Click Here About ProMIS Neurosciences Inc. ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Investor Relations Contact: Carie Pierce, VP, Investor Relations & External Affairs

IR@promisneurosciences.com
## Recent Company News
- 2026-09-01 12:00 EST — [ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September](https://biopharmsignal.com/news/PMN/promis-neurosciences-to-participate-in-upcoming-conferences-and-events-in-septem-72fbc0d5) — Source: ProMIS Neurosciences
- 2026-08-13 20:00 EST — [ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights](https://biopharmsignal.com/news/PMN/promis-neurosciences-announces-second-quarter-2026-financial-results-and-provide-dfe7d789) — Source: ProMIS Neurosciences
- 2026-08-03 20:00 EST — [ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026](https://biopharmsignal.com/news/PMN/promis-neurosciences-to-report-second-quarter-2026-financial-results-and-busines-ddaf05d1) — Source: ProMIS Neurosciences
- 2026-07-28 10:00 EST — [ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial](https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-positive-blinded-six-month-interim-safety-and-bioma-90dad1c6) — Source: ProMIS Neurosciences
- 2026-07-27 20:00 EST — [ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease](https://biopharmsignal.com/news/PMN/promis-neurosciences-to-host-webinar-to-discuss-upcoming-6-month-blinded-interim-36c2d083) — Source: ProMIS Neurosciences
## Related News
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)
- 2026-09-04 20:05 EST — NTLA — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-250d5dd9)